ClinicalTrials.gg
CompletedNCT06423872Updated May 21, 2024

A SAD Study of ZT002 Injection in Healthy Participants

A Phase 1 interventional study of ZT002 and Placebo in Type 2 Diabetes Mellitus, sponsored by Beijing QL Biopharmaceutical Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by Beijing QL Biopharmaceutical Co.,Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jun 2023, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
685th of 767
28 · median 199
Started
2023
with 61 others
Phase 1
122 of 909
12 open now
Registered
671st of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 685th largest by enrollment of the 767 interventional ones that give a count, is one of 62 that started in 2023, is one of 122 in phase 1, and was the 671st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This study will comprise a randomized, parallel assignment, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability and pharmacokinetic study of ZT002 in healthy participants.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand the purpose, nature, methods, and potential adverse reactions of the experiment, voluntarily participate as a participant, comply with the requirements of this study, and sign an form.
  2. Healthy adults, age 18\~45 years, both inclusive, at time of informed consent.
  3. (BMI) between 19~27.0 kg/m2 both included. Male weight>55.0kg, famale weight>50.0kg.
  4. In good health, determined by no findings from medical history, physical examination, vital signs measurements, anterior and lateral chest X-ray,12-lead , and clinical laboratory evaluations(blood routine, blood biochemistry, coagulation function, and urine routine)at screening and before administration of study drug, as assessed by the Investigator.
  5. Female participants are required to abstain or use two effective methods simultaneously from 1 month before screening to 6 months after the last dose. Male participants are required to abstain or use two effective contraceptive methods simultaneously from the first dose to 6 months after the last dose: male participants are required to undergo surgical sterilization (such as vas deferens ligation) or use condoms correctly, or their spouse is required to use hormonal contraceptives approved by the National Medical Products Administration (such as contraceptive pills, patches, implantable or injectable preparations) or intrauterine devices (IUDs) or undergo surgical sterilization; Female subjects may undergo surgical sterilization (such as tubal ligation) or intrauterine devices (IUDs), or their spouses may use condoms correctly or undergo surgical sterilization. After the trial, female subjects may also use hormone contraceptives approved by the National Medical Products Administration (such as contraceptive pills, patches, implantable or injectable preparations).

Exclusion criteria

Exclusion Criteria:

  1. History of drug allergy or allergic related diseases (allergic rhinitis, asthma, urticaria, eczema, etc.),allergic to experimental drugs and or GLP-1 class drugs.
  2. Significant history or clinical manifestation of any neurological, cardiovascular, hematological, hepatic, renal, gastrointestinal, respiratory, metabolic, endocrine, immune or skeletal, as determined by the Investigator.
  3. Family or personal history of medullary thyroid carcinoma (MTC).
  4. Medical history of multiple endocrine neoplasia type 2(MEN2).
  5. History of acute or chronic pancreatitis.
  6. History of hypoglycemia.
  7. Calcitonin equal or above 50 ng/L at screening.
  8. The content of amylase or lipase during the screening period is higher than the values and has clinical significance.
  9. Screening period HbAlc () ≥ 6.5%.
  10. According to the Fridericias formula, ≥ 450 ms for subjects in 12-lead examination during screening or baseline period.
  11. History of drug abuse within the previous year of screening or positive results from drug abuse screening (urine screening).
  12. Have smoked ≥5 cigarettes per day in the past 3 month prior to Screening or unable to refrain from smoking during the study.
  13. Screening for subjects who have consumed more than 14 units of alcohol per week within the first 3 months (1 unit of alcohol=360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine), or who have taken alcoholic products within 48 hours before administration, or who cannot abstain from alcohol during the trial period.
  14. Positive test for surface antigen (HBsAg), antibody (HCV-Ab), (HIV-Ab) antibody, treponema pallidum(TP-Ab) antibody at screening.
  15. Screening for subjects who have participated in other clinical trials and received drug therapy or medical device intervention within the first 3 months.
  16. Blood donation or blood loss - more than 400 mL during the 3 months prior to screening, or received blood transfusion; or blood donation or blood loss - more than 200 mL during the 1 months prior to screening.
  17. History of infectious diseases within 4 weeks before screening (judged by the investigator to affect the ability of the subject to participate in the test)
  18. Cannot tolerate venous puncture blood collection or have a history of fainting or fainting
  19. Received vaccination within 28 days prior to administration or plan to receive vaccination during the study period.
  20. Use of prescription or non-prescription or chinese herbal medicine or discontinue medication before 1 month to screening or within 5 half-lives of the medicinal product, (whichever is longest).
  21. Participant is unable to refrain from strenuous exercise during the study
  22. Breastfeeding or pregnant women, or positive tests of pregnancy in screening or baseline
  23. Other unsuitable conditions to participate in the clinical study judged by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    ZT002

    Participants will be randomized to receive ZT002 injection or Placebo in 1 of 6 dose cohorts.

    Drug: ZT002

  • Placebo comparator
    Placebo

    Participants will be randomized to receive ZT002 injection or Placebo in 1 of 6 dose cohorts.

    Other: Placebo

Interventions

  • DrugZT002

    Participants will receive a single subcutaneous (SC) ZT002 injection.

  • OtherPlacebo

    Participants will receive same volume as of the study drug.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of a single escalation dose of ZT002 through the incidence and severity of treatment emergent adverse events in SAD Cohorts. Number of participants with treatment-emergent adverse events

    Coded by the most updated version of the Medical Dictionary for Regulatory Activities (MedDRA).

    Time frame: Up to 50 days

  2. Safety and tolerability of a single escalation dose of ZT002 through the incidence severity of serious adverse events in SAD Cohorts. Number of participants with serious adverse events.

    Coded by the most updated version of the Medical Dictionary for Regulatory Activities (MedDRA).

    Time frame: Up to 50 days

Secondary outcomes

  1. The Pharmacokinetics (PK) profile of a single escalation dose of ZT002 in healthy participants in SAD Cohorts.

    Parameter: Maximum observed plasma concentration of ZT002 (Cmax)

    Time frame: Up to 50 days

  2. The Pharmacokinetics (PK) profile of a single escalation dose of ZT002 in healthy participants in SAD Cohorts.

    Parameter: Area under the drug-time curve from 0 h after dosing to the last quantifiable concentration time point (AUC0-last)

    Time frame: Up to 50 days

  3. The Pharmacokinetics (PK) profile of a single escalation dose of ZT002 in healthy participants in SAD cohorts.

    Parameter: Area under the drug-time curve to infinity (AUC0-inf)

    Time frame: Up to 50 days

07

Study locations

1 site
  • Beijing Hospital
    Beijing, Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Oct 2023, 4 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 4 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
May 21, 2024
StartActual
Jun 19, 2023
Primary completionActual
Oct 20, 2023
CompletionActual
Dec 8, 2023
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06423872
Collaborators
Beijing Hospital
Responsible party
Sponsor
First posted
May 21, 2024
Start date
Jun 19, 2023
Primary completion
Oct 20, 2023
Completion
Dec 8, 2023
Last update
May 21, 2024

Study contacts

Aixin Shi, Master
principal investigator · No.1 Dahua Road, Dongdan, Dongcheng District, Beijing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZT002

Start the discussion